Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Orbimed Advisors Llc purchased 1,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Electra Therapeutics Stock Down 7.0%
ETRA stock traded down $0.95 during trading on Wednesday, reaching $12.67. The stock had a trading volume of 874,135 shares, compared to its average volume of 708,715. Electra Therapeutics, Inc. has a one year low of $12.50 and a one year high of $15.50.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
